On February 11th, Eevia Health Plc (publ) (“Eevia”) announced multiple new sales orders for products totaling EUR 54k, equivalent to SEK 619k, from various European and Asian customers. In addition, Eevia is currently participating in BIOFACH, the world’s leading trade fair for organic food, taking place in Germany.
Analyst Group’s View of the New Orders
The new orders following the opening day of BIOFACH 2025 highlight Eevia’s strong market position and the effectiveness of the Company’s distribution partnerships, particularly with BREKO in Germany. The total order value of EUR 54k, including repeat purchases from key markets such as Germany, Australia, and Taiwan, reflects consistent demand for Eevia’s product portfolio.
We would like to emphasize that the sale of berry extracts strongly indicates sustained demand for Eevia’s premium products, derived from wild-harvested bilberries from Finnish and Swedish forests. This is particularly encouraging as Eevia is currently progressing with the divestment of the Company’s berry-based extract manufacturing assets, valued at EUR 2.5–3.0m, highlighting the underlying value of these assets as the Company continues to generate repeat orders.
It is important to note that all products are in stock, enabling immediate delivery without additional production costs, which positively impacts working capital and cash flow. Consequently, the reduction in inventory is expected to further strengthen the Company’s financial position. Moreover, the recurring nature of these orders demonstrates strong customer retention, supporting sustained revenue growth moving forward.
Sales Orders and Participation at the leading trade fair BIOFACH
Eevia is currently participating in BIOFACH 2025, the world’s leading trade fair for organic food, taking place from February 11–14 in Nuremberg, Germany. The event brings together exhibitors and visitors from the organic and natural sectors worldwide. During last year’s edition (2024), BIOFACH saw impressive participation, with 2,561 exhibitors and 34,626 visitors from 128 countries.
Following the opening day of the trade fair, four customers placed sales orders totaling EUR 54k (equivalent to SEK 619k). These included two German customers through the Company’s distributor, BREKO, for the bilberry extract Feno-Myrtillus™ 36. One German order was for Fenoprolic™ Full Spectrum, a pine extract with a broad spectrum of oligomeric proanthocyanidins. Additionally, a small order for the tart cherry extract Feno-Ceraus™ 5 (containing 5% polyphenols) came from Australia, while an order from Taiwan for Feno-Myrtillus™ 25 amounted to approx. EUR 15k.
Eevia has all products in stock, enabling immediate delivery without the need for raw material purchases or production, which benefits cash flow. As these are repeat orders, further purchases from these customers are expected.
In summary, it is encouraging to see that Eevia’s current product portfolio continues to generate repeat orders from existing customers, validating the strong demand for its 100% organically certified plant extracts. Additionally, BIOFACH, the world’s leading trade fair for organic food, presents an excellent opportunity to showcase the Company’s robust product portfolio to prospective customers, potentially converting them into long-term, repeat clients.
How Analyst Group views Eevia Health as an investment
In Q4-24, Eevia launched a transformational restructuring plan to become a specialized provider of high-margin, science-backed health solutions, focusing on gut, kidney, and urinary health. By divesting assets related to Retinari™ and berry extract manufacturing, Eevia aims to streamline operations, enhance profitability, and adopt a capital-light business model, leveraging the Company’s expertise in bioactive compounds. This turnaround plan allows investors to retain exposure to former operations without the financial risks of plant extract production. With a clear strategy set by the new and experienced board, Eevia is well-positioned to capitalize on the expanding gut health market and recover to profitable growth, thereby unlocking the underlying value within the Company. Overall, Analyst Group believes the ongoing rights issue presents an attractive entry point for investors at a Pre-Money valuation of SEK 6.0m.
